Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
According to Novo Nordisk's latest financial reports the company's current EPS (TTM) is โน290.57. In 2016 the company made an earnings per share (EPS) of โน97.11.
Year | EPS | Change |
---|---|---|
2025 (TTM) | โน280.60 | |
2016 | โน97.11 |
Company | EPS | EPS differencediff. | Country |
---|---|---|---|
![]() Pfizer PFE | โน121.04 | -58.34% | ๐บ๐ธ USA |
![]() Eli Lilly LLY | โน1,076 | 270.29% | ๐บ๐ธ USA |
![]() Bristol-Myers Squibb BMY | โน233.37 | -19.68% | ๐บ๐ธ USA |
![]() Sanofi SNY | โน247.93 | -14.68% | ๐ซ๐ท France |